APA Zitierstil

Starr, P. (2015). Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL. Am Health Drug Benefits.

Chicago Zitierstil

Starr, Phoebe. "Adding Ibrutinib to Standard Therapy Reduces Disease Progression By 80% in Previously Treated Patients With CLL." Am Health Drug Benefits 2015.

MLA Zitierstil

Starr, Phoebe. "Adding Ibrutinib to Standard Therapy Reduces Disease Progression By 80% in Previously Treated Patients With CLL." Am Health Drug Benefits 2015.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.